BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman Sells 1,032 Shares

Key Points

• Troy Wichterman, CFO of BioLife Solutions, sold 1,032 shares of the company's stock at an average price of $26.83, totaling $27,688.56, resulting in a 0.56% decrease in his holdings.
• BioLife Solutions reported a loss of $0.33 per share in its latest earnings, significantly missing analysts' expectations, while revenue was higher than predicted at $25.42 million.
• Following various investment reports, BioLife Solutions currently holds a consensus rating of "Buy" with an average target price of $31.29.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 1,032 shares of the firm's stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $26.83, for a total value of $27,688.56. Following the completion of the transaction, the chief financial officer directly owned 184,186 shares of the company's stock, valued at $4,941,710.38. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, August 26th, Troy Wichterman sold 590 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total value of $15,009.60.
• On Monday, July 7th, Troy Wichterman sold 877 shares of BioLife Solutions stock. The stock was sold at an average price of $22.27, for a total value of $19,530.79.

BioLife Solutions Stock Performance

BioLife Solutions stock traded down $0.71 during midday trading on Friday, hitting $25.57. 562,596 shares of the company's stock were exchanged, compared to its average volume of 395,316. BioLife Solutions, Inc. has a 52-week low of $19.10 and a 52-week high of $29.55. The stock has a 50-day moving average price of $23.83 and a two-hundred day moving average price of $23.35. The company has a market cap of $1.22 billion, a P/E ratio of -213.07 and a beta of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The business had revenue of $25.42 million for the quarter, compared to analysts' expectations of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of BioLife Solutions in the fourth quarter worth about $31,000. State of Wyoming increased its holdings in shares of BioLife Solutions by 353.1% in the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock worth $44,000 after buying an additional 1,490 shares during the period. US Bancorp DE increased its holdings in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,528 shares during the period. Ameritas Investment Partners Inc. increased its holdings in shares of BioLife Solutions by 12.8% in the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider's stock worth $83,000 after buying an additional 441 shares during the period. Finally, GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after buying an additional 663 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Zacks Research raised BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. Finally, Stephens assumed coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $30.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.